Gelesis obesity treatment studies well, but critics still wary; Flamel's once-a-week exenatide garners positive preclinical results;

> Gelesis released data this week showing that its obesity treatment was effective, but a critic at The New York Times panned the result as "modest." Story

> Flamel Technologies demonstrated positive results in a preclinical trial of once-a-week exenatide for Type 2 diabetes. Release

> A study that sheds light on the structure of milk during digestion could lead to the development of a new drug delivery technique. More

> New drug delivery company EastGate Acquisitions pulled in a research grant from Ontario Brain Institute. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.